Natco Doubles Down On US With Ambitious ANDA Plan

23 Sep 2016

• By Penelope MacRae

One of India’s leading generic players, Natco Pharma, aims to file at least 10 ANDAs in the US in the next two years to expand its footprint in this key market as more medicines fall off the patent cliff, and analysts say the company - which is also considering new therapeutic areas - could be on the “verge of a breakout” in its US business.

Natco Pharma Ltd. made global headlines four years ago when India’s patent authority gave the mid-sized firm a compulsory license to produce a generic version of Bayer AG’s cancer drug Nexavar (sorafenib) at a price 97% below the patent-protected original.

Huge controversy ensued with pharma multinationals accusing India of flouting patent rights and predicting a wave of such licenses, which...